Drug intelligence / Profile preview

AJA003

Development stage: Preclinical
Lead developer: AJNA
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

AJA003 is an **IND-enabling, multi-cannabinoid botanical drug candidate** developed by AJNA BioSciences for **post-traumatic stress disorder**. AJNA describes it as a novel cannabinoid formula intended to provide a standardized pharmaceutical option for people with PTSD, including veterans who may otherwise use unregulated cannabinoid products. The program is reported to target cannabinoid receptors, but its precise cannabinoid composition, receptor selectivity, functional pharmacology, dosage form, and route of administration have not been publicly disclosed. ([ajnabiosciences.com](https://ajnabiosciences.com/pipeline/))

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on AJA003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJA003.

Explore the full profile